KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)DivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pfizer (PFE) Divestments (2020 - 2025)

Pfizer (PFE) has disclosed Divestments for 6 consecutive years, with -$6.3 billion as the latest value for Q3 2025.

  • On a quarterly basis, Divestments changed N/A to -$6.3 billion in Q3 2025 year-over-year; TTM through Dec 2025 was $6.3 billion, a 10.36% decrease, with the full-year FY2025 number at $6.3 billion, down 10.36% from a year prior.
  • Divestments was -$6.3 billion for Q3 2025 at Pfizer, down from $6.3 billion in the prior quarter.
  • In the past five years, Divestments ranged from a high of $6.3 billion in Q1 2025 to a low of -$6.3 billion in Q3 2025.
  • A 4-year average of $2.2 billion and a median of $3.5 billion in 2024 define the central range for Divestments.
  • Peak YoY movement for Divestments: soared 49600.0% in 2022, then skyrocketed 80.46% in 2025.
  • Pfizer's Divestments stood at -$8.0 million in 2021, then skyrocketed by 49600.0% to $4.0 billion in 2022, then fell by 10.38% to $3.5 billion in 2024, then tumbled by 277.2% to -$6.3 billion in 2025.
  • Per Business Quant, the three most recent readings for PFE's Divestments are -$6.3 billion (Q3 2025), $6.3 billion (Q2 2025), and $6.3 billion (Q1 2025).